Sergio Ribeiro
CEO
Radiolife
Radiolife develops advanced diagnostics by leveraging proprietary Radiofrequency technology and Artificial Intelligence. This platform delivers fast, accurate, and cost-effective results to improve pathology research and patient outcomes. The company focuses on democratizing healthcare by making sophisticated diagnostic tools accessible globally.
- Artificial Intelligence
- Hardware
- Healthcare Technology
- Medical Devices
Updated 7 months ago
Funding
Raised to date
$50KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Sergio Ribeiro
CEO
Product
Problem
Traditional diagnostic methods often require significant time, specialized reagents, and laboratory infrastructure, leading to delays in disease detection and intervention. This can result in suboptimal patient outcomes, particularly in settings where rapid, accessible testing is critical.
Solution
Radiolife offers the Cube Scan platform, a rapid, reagent-free diagnostic system that leverages proprietary radiofrequency (RF) technology and artificial intelligence (AI) for near-instantaneous analysis. The Cube Scan device provides signal-based detection of various biomarkers and pathogens, delivering results in under 20 seconds. This approach aims to democratize access to advanced diagnostics by enabling point-of-care testing and accelerating disease detection for more timely and targeted interventions. The platform is designed for versatility, supporting applications in veterinary medicine, environmental monitoring, and biomedical research.
Target Audience
The primary target audience includes veterinary clinics, environmental testing laboratories, and biomedical research institutions seeking efficient and rapid diagnostic solutions.
Features
- Cube Scan diagnostic device utilizing RF spectroscopy and AI for signal analysis.
- Processing latency of less than 20 seconds per analysis cycle for rapid results.
- Reagent-free operation, eliminating the need for consumables and reducing operational costs.
- Detection capabilities for viruses, bacteria, protozoa, cancer cells, and macromolecules.
- Compact and lightweight design (20 cm x 15 cm, 1.5 kg) suitable for point-of-care and screening applications.
- Low voltage power supply, compatible with battery or AC power.
- Operational frequency spectrum from 1–10 GHz.
- Data transmission via Wi-Fi, USB, and Bluetooth.
- Compatibility with various sample types including serum, urine, saliva, and other biological fluids.
- AI-driven spectral data processing with cloud-integrated analytics for enhanced diagnostic specificity.
- Smart app for mobile result viewing and management.